Amarin Corp. plc, of Dublin, said it plans to complete the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) cardiovascular outcomes study of Vascepa (icosapent ethyl), which was approved by the FDA as an adjunct to diet to reduce triglyceride levels in adult patients with severely high (> 500 mg/dL) triglyceride levels.